ImmunityBio (IBRX)
(Delayed Data from NSDQ)
$8.99 USD
+1.64 (22.31%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $8.87 -0.12 (-1.33%) 6:10 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for ImmunityBio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 266 | 107 | 317 | 66 | 52 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 28 | 33 | 17 | 9 | 4 |
Total Current Assets | 294 | 141 | 334 | 76 | 56 |
Net Property & Equipment | 146 | 144 | 83 | 54 | 61 |
Investments & Advances | 1 | 6 | 1 | 8 | 11 |
Other Non-Current Assets | 7 | 7 | 6 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 17 | 20 | 1 | 0 | 0 |
Deposits & Other Assets | 3 | 0 | 7 | 1 | 4 |
Total Assets | 504 | 362 | 469 | 152 | 143 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 432 | 299 | 0 | 0 |
Accounts Payable | 9 | 21 | 11 | 4 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 43 | 42 | 51 | 8 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 3 | 4 | 7 | 4 |
Total Current Liabilities | 58 | 501 | 369 | 25 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 577 | 0 | 0 | 0 | 0 |
Long-Term Debt | 105 | 241 | 306 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 311 | 22 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,090 | 812 | 713 | 34 | 22 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,375 | 1,931 | 1,720 | 872 | 783 |
Retained Earnings | -2,962 | -2,378 | -1,962 | -755 | -662 |
Other Equity | 1 | -2 | -2 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -586 | -450 | -244 | 117 | 121 |
Total Liabilities & Shareholder's Equity | 504 | 362 | 469 | 152 | 143 |
Total Common Equity | -586 | -450 | -244 | 117 | 121 |
Shares Outstanding | 667.70 | 400.30 | 397.60 | 109.00 | 98.30 |
Book Value Per Share | -0.88 | -1.12 | -0.61 | 1.08 | 1.23 |
Fiscal Year End for ImmunityBio, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 266 | 190 | 46 | 91 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 28 | 25 | 21 | 22 |
Total Current Assets | NA | 294 | 215 | 67 | 113 |
Net Property & Equipment | NA | 146 | 152 | 151 | 154 |
Investments & Advances | NA | 1 | 1 | 1 | 1 |
Other Non-Current Assets | NA | 7 | 7 | 7 | 7 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 17 | 18 | 19 | 20 |
Deposits & Other Assets | NA | 3 | 3 | 4 | 5 |
Total Assets | NA | 504 | 432 | 291 | 343 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 37 | 0 |
Accounts Payable | NA | 9 | 20 | 25 | 34 |
Current Portion Long-Term Debt | NA | 0 | 0 | 482 | 471 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 43 | 65 | 62 | 54 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 1 | 3 |
Total Current Liabilities | NA | 58 | 90 | 613 | 565 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 577 | 28 | 0 | 0 |
Long-Term Debt | NA | 105 | 645 | 250 | 246 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 40 | 28 | 18 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 1,090 | 843 | 936 | 875 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 2,375 | 2,316 | 1,991 | 1,966 |
Retained Earnings | NA | -2,962 | -2,728 | -2,633 | -2,495 |
Other Equity | NA | 1 | 2 | -3 | -3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -586 | -411 | -645 | -532 |
Total Liabilities & Shareholder's Equity | NA | 504 | 432 | 291 | 343 |
Total Common Equity | 0 | -586 | -411 | -645 | -532 |
Shares Outstanding | 677.00 | 667.70 | 667.70 | 440.60 | 435.90 |
Book Value Per Share | 0.00 | -0.88 | -0.62 | -1.46 | -1.22 |